Introduction: Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods: We retrospectively evaluated 679 zanubrutinib-treated patients across 52 Italian centers, with 354 historical ibrutinib-treated controls. Shanafelt AF scores were assessed. Results: Nine zanubrutinib-treated patients developed AF (1.33%) during median treatment of 15.5 months, versus 42 historical controls (11.9%) over median observation of 25 months. Five zanubrutinib events occurred among patients scoring ≥ 5. No affected patients experienced embolic or bleeding complications. Conclusion: AF was uncommon during zanubrutinib treatment, even in the higher-risk subgroup. Historical comparisons remain limited, and exploratory score findings require confirmation with longer follow-up. Trial registration: The authors have confirmed clinical trial registration is not needed for this submission.

Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control

Innao, Vanessa;Allegra, Alessandro;Fabro, Vittorio Del;Stagno, Fabio;
2026-01-01

Abstract

Introduction: Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods: We retrospectively evaluated 679 zanubrutinib-treated patients across 52 Italian centers, with 354 historical ibrutinib-treated controls. Shanafelt AF scores were assessed. Results: Nine zanubrutinib-treated patients developed AF (1.33%) during median treatment of 15.5 months, versus 42 historical controls (11.9%) over median observation of 25 months. Five zanubrutinib events occurred among patients scoring ≥ 5. No affected patients experienced embolic or bleeding complications. Conclusion: AF was uncommon during zanubrutinib treatment, even in the higher-risk subgroup. Historical comparisons remain limited, and exploratory score findings require confirmation with longer follow-up. Trial registration: The authors have confirmed clinical trial registration is not needed for this submission.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3366891
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact